Researchers have introduced SC134-deruxtecan, a new antibody-drug conjugate designed to selectively target fucosyl-GM1 in small cell lung cancer (SCLC), a notoriously aggressive malignancy with limited treatment options. Preclinical data suggest enhanced specificity and potency, offering hope for improved patient outcomes in this challenging cancer subtype. This ADC exemplifies precision oncology efforts to develop targeted, tolerable therapies.